New drug combo for untreated advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new combination of drugs (Envafolimab, Cetuxima-β, and mFOLFOX6) for people with a specific type of advanced colorectal cancer that has not been treated yet. It aims to see if this combination is safe and more effective than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have advanced colorectal cancer that has spread (metastatic).
- Your tumor type is 'MSS' (microsatellite stable) and does not have mutations in the RAS or BRAF genes.
- You have not had any prior systemic treatment for your advanced cancer (chemotherapy, targeted therapy, or immunotherapy).
- You are physically able to do most daily activities (ECOG score 0 or 1).
- You have at least one measurable tumor on a CT or MRI scan.
- You have adequate organ function and no severe heart, lung, or bleeding conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a combination of drugs for colorectal cancer that has spread and hasn't responded to first-line treatment. It aims to see if these drugs can help control the cancer and improve outcomes for people in your situation.
This trial tests a combination of two targeted drugs (fruquintinib and a drug that targets EGFR) as a third-line treatment for people with a specific type of colorectal cancer that has not responded to previous therapies. It may offer a new option for patients whose tumors are 'wild-type' for certain genes.
This trial tests a combination of four drugs—bevacizumab, sintilimab, cetuximab, and irinotecan—in people whose colorectal cancer has spread and hasn't responded to previous treatments. The goal is to see if this new mix can shrink tumors or slow the cancer's growth.
This Phase 2 trial tests a combination of medicines (cetuximab, envafolimab, and chemotherapy) as the first treatment for certain left-sided metastatic colorectal cancers. It may help by slowing or shrinking the cancer in people whose tumor has no RAS/BRAF mutations and is microsatellite-stable (MSS).
This trial tests a new combination of targeted therapies for people with advanced colorectal cancer that has a certain genetic pattern (non-MSI-H, no BRAF V600E mutation). It aims to see if the combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of two drugs—cetuximab or bevacizumab plus a chemotherapy pill (trifluridine/tipiracil)—for people with metastatic colorectal cancer that has no RAS or BRAF mutations. It's for patients whose cancer grew after first responding to cetuximab, and who have had other treatments since then.
Hear when a new Metastatic Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.